Parcion Private Wealth Boosts Regeneron Pharmaceuticals Holdings

Investment firm increases stake in biotech company by 139.5% in Q4 2025

Apr. 17, 2026 at 11:41am

Got story updates? Submit your updates here. ›

A highly detailed, cinematic close-up image of heavy, industrial machinery and gears in shades of silver, steel, and chrome, conceptually representing the institutional power and financial infrastructure of the pharmaceutical industry.An extreme close-up of the inner workings of the pharmaceutical industry highlights the institutional strength and financial complexity behind innovative biotech companies.Tarrytown Today

Parcion Private Wealth LLC, a financial advisory firm, significantly increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter of 2025. The firm's position in the biopharmaceutical company grew by 139.5%, with its total holdings now valued at $913,000.

Why it matters

Regeneron Pharmaceuticals is a prominent biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. Parcion's increased investment signals confidence in the company's future growth prospects and the broader strength of the pharmaceutical sector.

The details

According to a recent SEC filing, Parcion Private Wealth acquired an additional 689 shares of Regeneron Pharmaceuticals during Q4 2025, bringing its total position to 1,183 shares. This represents a 139.5% increase in the firm's holdings, which were valued at $913,000 at the end of the quarter. The move comes as Regeneron's stock price has fluctuated between $476.49 and $821.11 over the past 52 weeks, reflecting the volatility in the biotech industry.

  • Parcion Private Wealth increased its Regeneron Pharmaceuticals holdings during the 4th quarter of 2025.
  • Regeneron Pharmaceuticals' stock price ranged from $476.49 to $821.11 over the past 52 weeks.

The players

Parcion Private Wealth LLC

A financial advisory firm that significantly increased its investment in Regeneron Pharmaceuticals during the fourth quarter of 2025.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company known for its innovative drug discovery technologies and pipeline of biologic therapies.

Got photos? Submit your photos here. ›

The takeaway

Parcion Private Wealth's increased stake in Regeneron Pharmaceuticals reflects the firm's confidence in the biotech company's growth potential and the broader strength of the pharmaceutical sector. This move highlights the continued investor interest in innovative drug developers like Regeneron, despite the volatility in the industry.